Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2014
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Duke University School of Medicine 2008
  • Ph.D., Duke University 2007
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2014 - 2017
• Research
• 

  Selected Grants

  • BMS CA209-848 2019 - 2024
  • MedImmune Panc D607C00005 2018 - 2023
  • A Phase 1/2 study of exploring the safety tolerablility and efficacy of Epacadostat in combination with Durvalumab in subjects with selected advanced solid tumors. 2016 - 2021
  • A platform study exploring the safety tolerability effects on the tumor microenvironment and efficacy of Pembroliumab (MK-3475) + INCB combination 2016 - 2021
  • A Phase I open label dose escalation safety and tolerability study of INCB054828 in subjects with advanced malignancies 2015 - 2020
  • AM0010-301 A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared 2017 - 2020
  • BACCI - RU021416 Phase II Study 2017 - 2020
  • A Phase 1/2 study of the safety, tolorability and efficacy of INCB24360 administered in combination with Nivolumab in select advanced cancers. 2015 - 2020
  • OncoMed OMP-313M32 2017 - 2019
  • ATELIER ML39832 PI Initiated 2018
  • A Phase 2 proof of concept study of ACP-196 alone in combination with Pembrolizumab in subjects with advanced or metastatic pancreatic cancer. 2015 - 2018
  • A Multi center study of the Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib in combination with MEDI4736 2015 - 2018
  • Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer awarded by Department of Defense 2016 - 2017
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Mettu, Niharika B., and James L. Abbruzzese. “Clinical Insights Into the Biology and Treatment of Pancreatic Cancer..” J Oncol Pract 12, no. 1 (January 2016): 17–23. https://doi.org/10.1200/JOP.2015.009092.
       Full Text  Open Access Copy  Link to Item
    • Mettu, Niharika B., Herbert Hurwitz, and David S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer..” Oncology (Williston Park) 27, no. 8 (August 2013): 746–54.
       Link to Item
    • Mettu, N. B., H. Hurwitz, and D. S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer.” Oncology (United States) 27, no. 8 (January 1, 2013).
    • Stanifer, John, Reema Mehta, Niharika Mettu, Jeffrey Sanders, and Noppon Setji. “Muehrcke's lines as a diagnostic clue to increased catabolism and a severe systemic disease state..” Am J Med Sci 342, no. 4 (October 2011). https://doi.org/10.1097/MAJ.0b013e31821fb6d0.
       Full Text  Link to Item
    • Mettu, Niharika B., Thomas B. Stanley, Mary A. Dwyer, Michelle S. Jansen, John E. Allen, Julie M. Hall, and Donald P. McDonnell. “The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors..” Mol Endocrinol 21, no. 10 (October 2007): 2361–77. https://doi.org/10.1210/me.2007-0201.
       Full Text  Link to Item

  • Conference Papers

    • Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors..” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.